Accolade Inc - ACCD Net earnings per share for the last 12 months

Public company logo of Accolade Inc (ACCD)

The year-over-year percentage growth of earnings per share over 12 months for Accolade (ACCD) demonstrates a trend where 75.70 reflects the latest metric value. Major US employers value the brand for its personalized healthcare navigation. The high authority of the executives guarantees the transparency of B2B metrics. Stable cash flow is ensured by long-term corporate subscriptions, which support the operational resilience of the business.

accolade.com (ACCD): Earnings per share for the last twelve months from 02/11/2024 to 02/20/2024

Accolade Health - analytical breakdowns and key metrics (ACCD)

- market value and analyst target forecast:
Stock Quotes Accolade|ACCD - Analyst Consensus Forecast
- issuer market value details:
Market Valuation Accolade Inc|ACCD - Total Company Value
- book capitalization data:
Net Asset Value per Share Accolade|ACCD - Company Book Value|Market Value to Book Value Ratio accolade.com|ACCD - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Accolade|ACCD - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Accolade|ACCD - Company Aggregate Debts|Debts to Book Value Accolade Inc|ACCD - Company Long-Term Debts|Company Short-Term Debts Accolade|Quick Liquidity Indicator accolade.com
- net income and valuation ratios data:
ACCD - Net Profit|Future Profit Accolade|ACCD - P/E Multiple|Price to Future Earnings Ratio Accolade|ACCD - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Accolade Inc|ACCD - Operating profit EBITDA|Net earnings per one share for the last twelve months Accolade|ACCD - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months accolade.com|ACCD - Earnings growth in current year|Expected net earnings per share growth next year Accolade
Fundamental company valuation:ACCD, Accolade, Inc.
Mass-produced product of Accolade, Inc.

Accolade competes by reducing employer healthcare costs through AI-driven personalization. The earnings per share trend quantifies client retention efficiency and the platform's actual ROI. This metric calculates the annual change in net income over a trailing twelve-month period, smoothing out quarterly gaps. It is critical for investors to distinguish sustainable growth from short-term spikes. Analyzing historical year-over-year EPS growth (TTM) helps verify fundamental momentum.

Competitor analysis for Accolade

forhims.com (HIMS) - Net earnings per share for the last 12 months|HNGE: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Teladoc Health|Earnings per share for the last twelve months Talkspace Corp|Net earnings per one share for the last twelve months LifeMD Corp LFMD|Earnings per share for the last twelve months American Well (AMWL)|Earnings per share for the last twelve months MGRX (mangorx.com)|Net earnings per share (EPS TTM) DRIO (DarioHealth)|Net earnings per share (EPS TTM) VSee Health Inc VSEE|MANADR - Net earnings per share (EPS TTM)|BTCY (Biotricity Inc) - Earnings per share for the last 12 months|LYT: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months ontrak-inc.com (OTRK)|SHLT (SHL Telemedicine Ltd) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Thorne HealthTech Inc